PMID- 27611583
OWN - NLM
STAT- MEDLINE
DCOM- 20170808
LR  - 20221207
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 11
IP  - 9
DP  - 2016
TI  - Association of Human Leukocyte Antigen DRB1*15 and DRB1*15:01 Polymorphisms with 
      Response to Immunosuppressive Therapy in Patients with Aplastic Anemia: A 
      Meta-Analysis.
PG  - e0162382
LID - 10.1371/journal.pone.0162382 [doi]
LID - e0162382
AB  - This study aimed to review and quantitatively analyze (1) the association of 
      aplastic anemia (AA) with human leukocyte antigen (HLA)-DRB1*15 and 
      HLA-DRB1*15:01 polymorphisms and (2) the association of HLA-DRB1*15 and 
      HLA-DRB1*15:01 polymorphisms with response to immunosuppressive therapy (IST) in 
      AA. Published studies have reported conflicting and heterogeneous results 
      regarding the association of HLA-DRB1*15 and HLA-DRB1*15:01 polymorphisms with 
      response to IST in AA. The PubMed, Embase, Cochrane Library, China National 
      Knowledge Infrastructure, Chinese BioMedical Literature, Wangfang and Chinese 
      Social Sciences Citation Index databases were searched. All relevant publications 
      were searched through December 2015. Odds ratio (OR), risk ratio (RR), and 95% 
      confidence intervals (CI) for the comparison between case-control or cohort 
      studies were evaluated. Finally, 24 articles were identified. For HLA-DRB1*15 and 
      HLA-DRB1*15:01, the OR (95% CI) was 2.24(1.33-3.77), P < 0.01 and 
      2.50(1.73-3.62), P < 0.01, respectively; and the overall pooled RR was 1.72 
      (1.30-2.29), P < 0.01 and 1.59 (1.29-1.96), P < 0.01, respectively. Statistical 
      evidence showed no publication bias (P > 0.05). Sensitivity analyses revealed 
      that the results were statistically robust. The meta-analysis suggested that 
      HLA-DRB1*15 and HLA-DRB1*15:01 polymorphisms might be associated with increased 
      AA risk in Asians. IST might be more effective in HLA-DRB1*15+ and 
      HLA-DRB1*15:01+ Asian patients with AA than in HLA-DRB1*15- and HLA-DRB1*15:01- 
      Asian patients with AA. Future studies with adequate methodological quality on 
      gene-gene and gene-environment interactions and gene treatment may yield valid 
      results.
FAU - Liu, Shan
AU  - Liu S
AD  - Center of Clinical Evaluation and Analysis, Zhejiang Provincial Hospital of 
      Traditional Chinese Medicine, Hangzhou, Zhejiang, China.
FAU - Li, Qing
AU  - Li Q
AD  - Department of Hematology, Zhejiang Provincial Hospital of Traditional Chinese 
      Medicine, Hangzhou, Zhejiang, China.
FAU - Zhang, Ying
AU  - Zhang Y
AD  - Center of Clinical Evaluation and Analysis, Zhejiang Provincial Hospital of 
      Traditional Chinese Medicine, Hangzhou, Zhejiang, China.
FAU - Li, Qiushuang
AU  - Li Q
AD  - Center of Clinical Evaluation and Analysis, Zhejiang Provincial Hospital of 
      Traditional Chinese Medicine, Hangzhou, Zhejiang, China.
FAU - Ye, Baodong
AU  - Ye B
AD  - Department of Hematology, Zhejiang Provincial Hospital of Traditional Chinese 
      Medicine, Hangzhou, Zhejiang, China.
FAU - Wu, Dijiong
AU  - Wu D
AD  - Department of Hematology, Zhejiang Provincial Hospital of Traditional Chinese 
      Medicine, Hangzhou, Zhejiang, China.
FAU - Wu, Li
AU  - Wu L
AD  - Center of Clinical Evaluation and Analysis, Zhejiang Provincial Hospital of 
      Traditional Chinese Medicine, Hangzhou, Zhejiang, China.
FAU - Lu, Hanti
AU  - Lu H
AD  - Center of Clinical Evaluation and Analysis, Zhejiang Provincial Hospital of 
      Traditional Chinese Medicine, Hangzhou, Zhejiang, China.
FAU - Ji, Conghua
AU  - Ji C
AD  - Center of Clinical Evaluation and Analysis, Zhejiang Provincial Hospital of 
      Traditional Chinese Medicine, Hangzhou, Zhejiang, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20160909
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (HLA-DRB1 Chains)
RN  - 0 (Immunosuppressive Agents)
SB  - IM
MH  - Alleles
MH  - Anemia, Aplastic/*drug therapy/*genetics
MH  - Asian People
MH  - Gene Frequency
MH  - Genetic Predisposition to Disease
MH  - Genotype
MH  - HLA-DRB1 Chains/*genetics
MH  - Humans
MH  - Immunosuppressive Agents/*therapeutic use
MH  - Odds Ratio
MH  - *Pharmacogenomic Variants
MH  - *Polymorphism, Genetic
MH  - Publication Bias
MH  - Treatment Outcome
PMC - PMC5017877
COIS- The authors have declared that no competing interests exist.
EDAT- 2016/09/10 06:00
MHDA- 2017/08/09 06:00
PMCR- 2016/09/09
CRDT- 2016/09/10 06:00
PHST- 2016/02/23 00:00 [received]
PHST- 2016/08/22 00:00 [accepted]
PHST- 2016/09/10 06:00 [entrez]
PHST- 2016/09/10 06:00 [pubmed]
PHST- 2017/08/09 06:00 [medline]
PHST- 2016/09/09 00:00 [pmc-release]
AID - PONE-D-16-01527 [pii]
AID - 10.1371/journal.pone.0162382 [doi]
PST - epublish
SO  - PLoS One. 2016 Sep 9;11(9):e0162382. doi: 10.1371/journal.pone.0162382. 
      eCollection 2016.